SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following media reports that GameStop is building a stake in the company as a potential acquisition target, sparking widespread debate among investors over the financial feasibility and strategic logic of a merger. Community discussions are highly polarized, with many skeptical of the deal's mechanics while others are closely tracking institutional data and potential share accumulation patterns.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is currently in the spotlight following the announcement of a preliminary Phase 3 trial design for its lead candidate, CAD-1005, aimed at treating heparin-induced thrombocytopenia. While some community members are optimistic about the company's clinical pipeline and potential regulatory progress, others are expressing significant skepticism due to heavy bot-driven social media activity and concerns over the company's long-term capital needs.

Urban One, Inc. is a multi-media company, which engages in radio broadcasting that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment consists of all radio broadcast results of operations and low powered television operations. The Reach Media segment consists of the results of operations for the related activities and operations of the company’s syndicated shows. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One and CLEO TV operations. The company was founded by Catherine L. Hughes in 1980 and is headquartered in Silver Spring, MD.

Urban One Inc - Ordinary Shares - Class A

Urban One Inc

Urban One is gaining traction as investors speculate on a potential rally leading up to Juneteenth, a trend that has historically drawn significant attention to the stock. The conversation is currently fueled by discussions around micro-float mechanics, recent acquisition news, and comparisons to previous parabolic moves.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as the community debates its potential to break through previous highs and drop a zero amidst high social media activity. While some traders express skepticism regarding its longevity, others are actively encouraging aggressive accumulation and engagement to fuel a rally.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Investors are actively debating the potential for an acquisition or significant strategic shift as the company continues to hold substantial cash relative to its market capitalization. Community sentiment remains polarized, with many stakeholders expressing frustration over recent management decisions while others look for catalysts like NCCN guideline updates for Rolvedon to unlock value.

Dumb SEND IT

The $DSIT (Dumb SEND IT) community is aggressively pushing for a breakout, driven by the anticipation of official chart integration and a forthcoming website launch. Holders are actively engaged in community-led pump efforts and air-drop incentives, positioning the token as a resilient, community-driven play against skeptics and early profit-takers.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi is currently attracting significant investor attention as market participants speculate on the company's M&A strategy, particularly regarding potential acquisitions in the obesity, MASH, and immunology sectors. Community discourse is heavily focused on Sanofi's recent pipeline developments and the perceived need for the pharmaceutical giant to expand its portfolio to counter long-term patent cliff challenges.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is experiencing high-volume momentum and renewed investor interest as community discussions intensify around the potential for a strategic buyout or partnership. While long-term shareholders remain wary due to past volatility and management changes, the consistent uptick in volume has fueled speculation that material news or a liquidity event may be imminent.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul Cahill Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest is experiencing significant volatility as investors react to a revenue miss and cautious forward guidance, while the community actively debates whether the stock is an oversold value opportunity or a long-term play in need of new leadership. Sentiment remains divided between those betting on a technical bounce supported by the company's strong cash position and those frustrated by management's inability to capitalize on a large, active user base.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun Inc. is attracting intense investor attention as its stock faces significant volatility driven by a major $500 million joint venture with HASI to accelerate residential solar and storage adoption. While the community remains deeply polarized between bulls betting on a rebound based on long-term energy independence and bears expressing frustration over recent price declines and sector headwinds, the stock continues to be a central focus of short-squeeze speculation and heavy institutional interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Analysts

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been given a consensus rating of "Buy" by the eight research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and two have...

Eyepoint Pharmaceuticals (EYPT) to Release Quarterly Earnings on Wednesday

Eyepoint Pharmaceuticals (NASDAQ:EYPT) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Sells $36,555.00 in Stock

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction on Friday, April 17th. The shares were sold...

Insider Selling: Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Sells 2,437 Shares of Stock

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $15.00, for a total value of $36,555.00. The sale was disclosed...

JPMorgan Chase & Co. Sells 217,150 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT

JPMorgan Chase & Co. cut its stake in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 87.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,262 shares of the company's stock after selling 217,150 share...

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Buy" by Brokerages

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has earned a consensus recommendation of "Buy" from the eight brokerages that are currently covering the company, Marketbeat reports...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 3.7% - Time to Sell?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 3.7% - Time to Sell...

Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT

Aberdeen Group plc boosted its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 101.6% in the 4th quarter, according to its most recent filing with the Securities and...

Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?

Arvinas (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference

Executives from Eyepoint Pharmaceuticals (NASDAQ:EYPT) told investors at RBC Capital Markets' Ophthalmology Conference that the company's lead program, DURAVYU (vorolanib), is advancing through four...

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EYPT
EyePoint Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EYPT News

EYPTEyePoint Pharmaceuticals Inc